XML 100 R82.htm IDEA: XBRL DOCUMENT v3.25.4
Condensed Financial Information (Parent Company Only) - Schedule of Condensed Statements of Cash Flows Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Operating Activities:      
Net loss attributable to Alignment Healthcare, Inc. $ (724) $ (128,035) $ (148,017)
Adjustments to reconcile Net loss to net cash provided by (used in) operating activities:      
Amortization of debt issuance costs 1,761 1,293 1,254
Net cash provided by (used in) operating activities 139,927 34,770 (59,187)
Investing Activities:      
Investment in Subsidiary (65,633) (82,200) (379,058)
Net cash provided by (used in) investing activities (14,974) 39,191 (147,263)
Financing Activities:      
Shares withheld net of restricted stock 0 (350) 0
Stock options exercised 18,067 155 0
Proceeds from long-term debt 0 380,000 0
Debt issuance costs (26) (8,792) 0
Net cash provided by financing activities 18,041 156,028 105
Net (decrease) increase in cash 142,994 229,989 (206,345)
Cash, cash equivalents and restricted cash at beginning of period 434,943 204,954 411,299
Cash, cash equivalents and restricted cash at end of period 577,937 434,943 204,954
Supplemental non-cash financing and investing activities:      
Debt issuance costs in accounts payable 0 512 0
Parent Company      
Operating Activities:      
Net loss attributable to Alignment Healthcare, Inc. (724) (128,035) (148,017)
Adjustments to reconcile Net loss to net cash provided by (used in) operating activities:      
Equity in loss of subsidiary (15,100) 125,892 147,529
Amortization of debt issuance costs 1,761 220 0
Due to subsidiary 14,063 1,923 488
Net cash provided by (used in) operating activities 0 0 0
Investing Activities:      
Investment in Subsidiary (18,068) (321,525) 0
Net cash provided by (used in) investing activities (18,068) (321,525) 0
Financing Activities:      
Shares withheld net of restricted stock 0 (350) 0
Stock options exercised 18,068 155 0
Proceeds from long-term debt 0 330,000 0
Debt issuance costs 0 (8,280) 0
Net cash provided by financing activities 18,068 321,525 0
Net (decrease) increase in cash 0 0 0
Cash, cash equivalents and restricted cash at beginning of period 0 0 0
Cash, cash equivalents and restricted cash at end of period 0 0 0
Supplemental non-cash financing and investing activities:      
Contribution of equity to subsidiary related to equity-based compensation 62,082 71,132 66,835
Debt issuance costs in accounts payable $ 26 $ 512 $ 0